alfuzosin has been researched along with Lower Urinary Tract Symptom in 14 studies
alfuzosin: structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this study was to assess the efficacy and safety of alfuzosin 10 mg monotherapy or combined antihypertensive medication on blood pressure (BP) in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH/LUTS) with or without antihypertensive medication." | 9.20 | Multicenter, prospective, comparative cohort study evaluating the efficacy and safety of alfuzosin 10 mg with regard to blood pressure in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia with or without antihypertensive med ( Chung, WS; Hyun, JS; Kim, SW; Lee, SW; Min, KS; Moon, DG; Moon, KH; Park, JK; Park, K; Ryu, JK; Yang, DY; Yang, SK; Zhang, LT, 2015) |
| "The efficacy and safety of treatment with alfuzosin 10 mg plus propiverine 10 or 20 mg in men with lower urinary tract symptoms (LUTS) and an overactive bladder were investigated." | 9.19 | Comparison of alfuzosin 10 mg with or without propiverine 10 mg, 20 mg in men with lower urinary tract symptom and an overactive bladder: randomised, single-blind, prospective study. ( Cho, HJ; Cho, JM; Kang, JY; Moon, HS; Seo, DY; Shin, SC; Sung, LH; Yoo, TK; Yu, JH, 2014) |
| "The aim of this study was to assess patient outcome after discontinuation of alfuzosin treatment in patients with benign prostatic hyperplasia (BPH)." | 9.17 | Evaluation of patient outcome after discontinuation of alfuzosin treatment for benign prostatic hyperplasia: a multicentre, prospective study. ( Chung, JH; Han, JH; Jo, JK; Kang, DH; Kim, TH; Lee, JW; Lee, JY; Lee, KS; Lee, SH; Lee, SW, 2013) |
| "The present study was designed to compare the efficacy of alfuzosin therapy as an alpha-blocker in metabolic syndrome (MetS) and non-MetS patients with moderate lower urinary tract symptoms (LUTS)." | 7.96 | Efficacy of Alfuzosin in Male Patients with Moderate Lower Urinary Tract Symptoms: Is Metabolic Syndrome a Factor Affecting the Outcome? ( Demirtas, A; Keske, M; Sonmez, G; Topaloglu, US, 2020) |
| "To assess the effect of alfuzosin (XATRAL) 10 mg once daily on sexual function in men with moderate to severe lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH), patients with suggestive symptomatic BPH, an International Prostate Symptom Score (IPSS) >8 (range of scores, 0-35), and sexual attempts at least once per month were enrolled." | 7.78 | Impact of alfuzosin on sexual function in Taiwanese men with benign prostatic hyperplasia. ( Chang, HC; Chen, CS; Chen, WH; Chiang, PH; Chu, SH; Hwang, TI; Lee, LM; Lin, MS; Yeh, SD, 2012) |
| "Silodosin is a novel, more selective alpha-blocker, which is specific to the lower urinary tract and may have fewer side effects than other alpha-blockers." | 6.55 | Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. ( Dahm, P; Jung, JH; Kim, J; Kim, MH; MacDonald, R; Reddy, B, 2017) |
| " The follow-up included 3 visits: visit of inclusion in the program of patients with a previously prescribed drug of Alfuprost MR in a dosage of 10 mg once a day (visit "0"), visit 1 at 30 days (+/-5 days) later, and visit 2 at 90 days (+/-5 days) after inclusion in the study." | 5.72 | [The influence of alfuzosin monotherapy on the sexual function of patients with benign prostatic hyperplasia in real clinical practice (results of a Russian multicenter study)]. ( Bernikov, AN; Loran, OB; Pushkar, DY, 2022) |
| "The objective of this study was to assess the efficacy and safety of alfuzosin 10 mg monotherapy or combined antihypertensive medication on blood pressure (BP) in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH/LUTS) with or without antihypertensive medication." | 5.20 | Multicenter, prospective, comparative cohort study evaluating the efficacy and safety of alfuzosin 10 mg with regard to blood pressure in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia with or without antihypertensive med ( Chung, WS; Hyun, JS; Kim, SW; Lee, SW; Min, KS; Moon, DG; Moon, KH; Park, JK; Park, K; Ryu, JK; Yang, DY; Yang, SK; Zhang, LT, 2015) |
| "The efficacy and safety of treatment with alfuzosin 10 mg plus propiverine 10 or 20 mg in men with lower urinary tract symptoms (LUTS) and an overactive bladder were investigated." | 5.19 | Comparison of alfuzosin 10 mg with or without propiverine 10 mg, 20 mg in men with lower urinary tract symptom and an overactive bladder: randomised, single-blind, prospective study. ( Cho, HJ; Cho, JM; Kang, JY; Moon, HS; Seo, DY; Shin, SC; Sung, LH; Yoo, TK; Yu, JH, 2014) |
| "The aim of this study was to assess patient outcome after discontinuation of alfuzosin treatment in patients with benign prostatic hyperplasia (BPH)." | 5.17 | Evaluation of patient outcome after discontinuation of alfuzosin treatment for benign prostatic hyperplasia: a multicentre, prospective study. ( Chung, JH; Han, JH; Jo, JK; Kang, DH; Kim, TH; Lee, JW; Lee, JY; Lee, KS; Lee, SH; Lee, SW, 2013) |
| "The present study was designed to compare the efficacy of alfuzosin therapy as an alpha-blocker in metabolic syndrome (MetS) and non-MetS patients with moderate lower urinary tract symptoms (LUTS)." | 3.96 | Efficacy of Alfuzosin in Male Patients with Moderate Lower Urinary Tract Symptoms: Is Metabolic Syndrome a Factor Affecting the Outcome? ( Demirtas, A; Keske, M; Sonmez, G; Topaloglu, US, 2020) |
| "To assess the effect of alfuzosin (XATRAL) 10 mg once daily on sexual function in men with moderate to severe lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH), patients with suggestive symptomatic BPH, an International Prostate Symptom Score (IPSS) >8 (range of scores, 0-35), and sexual attempts at least once per month were enrolled." | 3.78 | Impact of alfuzosin on sexual function in Taiwanese men with benign prostatic hyperplasia. ( Chang, HC; Chen, CS; Chen, WH; Chiang, PH; Chu, SH; Hwang, TI; Lee, LM; Lin, MS; Yeh, SD, 2012) |
| "Silodosin is a novel, more selective alpha-blocker, which is specific to the lower urinary tract and may have fewer side effects than other alpha-blockers." | 2.55 | Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. ( Dahm, P; Jung, JH; Kim, J; Kim, MH; MacDonald, R; Reddy, B, 2017) |
| " The follow-up included 3 visits: visit of inclusion in the program of patients with a previously prescribed drug of Alfuprost MR in a dosage of 10 mg once a day (visit "0"), visit 1 at 30 days (+/-5 days) later, and visit 2 at 90 days (+/-5 days) after inclusion in the study." | 1.72 | [The influence of alfuzosin monotherapy on the sexual function of patients with benign prostatic hyperplasia in real clinical practice (results of a Russian multicenter study)]. ( Bernikov, AN; Loran, OB; Pushkar, DY, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 12 (85.71) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Pushkar, DY | 1 |
| Loran, OB | 1 |
| Bernikov, AN | 1 |
| Sonmez, G | 1 |
| Topaloglu, US | 1 |
| Keske, M | 1 |
| Demirtas, A | 1 |
| Jung, JH | 1 |
| Kim, J | 1 |
| MacDonald, R | 1 |
| Reddy, B | 1 |
| Kim, MH | 1 |
| Dahm, P | 1 |
| Shim, KH | 1 |
| Kim, TW | 1 |
| Chung, BH | 1 |
| Lee, SW | 3 |
| Park, JK | 2 |
| Park, K | 2 |
| Cheon, J | 1 |
| Lee, KS | 2 |
| Kim, HJ | 1 |
| Seong, DH | 1 |
| Oh, SJ | 1 |
| Kim, SW | 2 |
| Lee, JY | 2 |
| Choo, SH | 1 |
| Choi, JB | 1 |
| Jian, Z | 1 |
| Chen, Y | 1 |
| Liu, Q | 1 |
| Liao, B | 1 |
| Yang, T | 1 |
| Li, H | 1 |
| Wang, K | 1 |
| Praus, F | 1 |
| Miernik, A | 1 |
| Chung, JH | 1 |
| Kang, DH | 1 |
| Jo, JK | 1 |
| Lee, JW | 1 |
| Lee, SH | 1 |
| Kim, TH | 1 |
| Han, JH | 1 |
| Cho, HJ | 1 |
| Shin, SC | 1 |
| Seo, DY | 1 |
| Cho, JM | 1 |
| Kang, JY | 1 |
| Yoo, TK | 1 |
| Yu, JH | 1 |
| Sung, LH | 1 |
| Moon, HS | 1 |
| Bulut, S | 1 |
| Ozden, C | 1 |
| Aktas, BK | 1 |
| Deren, T | 1 |
| Tagci, S | 1 |
| Gokkaya, CS | 1 |
| Baykam, MM | 1 |
| Memis, A | 1 |
| Salah Azab, S | 1 |
| Elsheikh, MG | 1 |
| Umul, M | 1 |
| Altay, AB | 1 |
| Bademkiran, F | 1 |
| Turna, B | 1 |
| Semerci, MB | 1 |
| Apaydin, E | 1 |
| Cikili, N | 1 |
| Zhang, LT | 1 |
| Chung, WS | 1 |
| Hyun, JS | 1 |
| Moon, DG | 1 |
| Yang, SK | 1 |
| Ryu, JK | 1 |
| Yang, DY | 1 |
| Moon, KH | 1 |
| Min, KS | 1 |
| Liu, S | 1 |
| Yu, Y | 1 |
| Gao, Y | 1 |
| Yang, X | 1 |
| Pang, Z | 1 |
| Hwang, TI | 1 |
| Chu, SH | 1 |
| Lin, MS | 1 |
| Chen, CS | 1 |
| Lee, LM | 1 |
| Chang, HC | 1 |
| Yeh, SD | 1 |
| Chen, WH | 1 |
| Chiang, PH | 1 |
3 reviews available for alfuzosin and Lower Urinary Tract Symptom
| Article | Year |
|---|---|
Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Humans; Indoles; Lower Urinary Tract Symptoms; Male; | 2017 |
Combination of solifenacin and tamsulosin may provide additional beneficial effects for ureteral stent-related symptoms-outcomes from a network meta-analysis.
Topics: Drug Therapy, Combination; Humans; Lower Urinary Tract Symptoms; Network Meta-Analysis; Pain; Quinaz | 2019 |
[LUTS in BPH patients : Comparison of silodosin versus tamsulosin, naftopidil, alfuzosin and placebo for the treatment of lower urinary tract symptoms].
Topics: Adrenergic alpha-1 Receptor Antagonists; Humans; Indoles; Lower Urinary Tract Symptoms; Male; Naphth | 2019 |
4 trials available for alfuzosin and Lower Urinary Tract Symptom
7 other studies available for alfuzosin and Lower Urinary Tract Symptom
| Article | Year |
|---|---|
[The influence of alfuzosin monotherapy on the sexual function of patients with benign prostatic hyperplasia in real clinical practice (results of a Russian multicenter study)].
Topics: Adrenergic alpha-Antagonists; Humans; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia; Qua | 2022 |
Efficacy of Alfuzosin in Male Patients with Moderate Lower Urinary Tract Symptoms: Is Metabolic Syndrome a Factor Affecting the Outcome?
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Humans; Lower Urinary Tract Symptoms; Male; Metabolic | 2020 |
Changes in autonomic nervous system activity after treatment with alpha-blocker in men with lower urinary tract symptoms.
Topics: Adrenergic alpha-Antagonists; Aged; Autonomic Nervous System; Heart Rate; Humans; Lower Urinary Trac | 2018 |
Effects of medical therapy or surgery on prostatic and bladder resistive indices in patients with benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Humans; Lower Urinary Tract Symptoms; Male; Middle Ag | 2015 |
The impact of the bladder wall thickness on the outcome of the medical treatment using alpha-blocker of BPH patients with LUTS.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Humans; Lower Urinary Tract Symptoms; Male; Middle Ag | 2015 |
The relationship between lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction: the role of autonomic hyperactivity.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Autonomic Nervous System; Blood Glucose; Body Mass In | 2014 |
Impact of alfuzosin on sexual function in Taiwanese men with benign prostatic hyperplasia.
Topics: Aged; Drug Administration Schedule; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male | 2012 |